Finansiering DiaGenic

Med referanse til halvårsrapport av 20. august med orientering om at Styret i DiaGenic arbeider med finansiering av selskapet, melder DiaGenic at selskapets ”market makers” Argo Securities og Orion Securities er valgt som finansielle rådgivere for arbeidet med en kapitalutvidelse. DiaGenic melder også at selskapet har akseptert et lånetilsagn på NOK 5 millioner fra Innovasjon Norge. Lånet har p.t. en rente på 5,75 % p.a.. Oslo, 21. oktober 2009 Styret i Diagenic ASA

Om oss

DiaGenic ASA is an innovative Norwegian life sciences company founded in 1998 and listed on the Oslo Stock Exchange. DiaGenic develops patient-friendly tests for the early diagnosis of devastating diseases where early intervention is crucial for successful treatment. DiaGenic’s patented method is based on identifying disease-specific gene signatures from easily available sample material such as blood. DiaGenic's strategy is to work with research and technology partners to develop a pipeline of assays for commercialisation by major diagnostics companies. Currently DiaGenic’s first two tests for the early detection of breast cancer and Alzheimer’s disease are on track to enter extensive clinical trials during 2007. The company has been awarded substantial development grants as part of the Norwegian Research Council’s FUGE programme.